Chronic hepatitis C virus (HCV) infection may negatively impact early human immunodeficiency virus (HIV) viral response to antiretroviral therapy (ART), a recent study found. HIV RNA was measured every 6 months among 441 women with HIV (WWH) in the Women’s Interagency HIV Study who initiated ART from 2000-2015. Log-binomial regression models were used to compare the proportion of study visits with detectable HIV RNA between women with and without chronic HCV. Researchers found:
- 114 (25%) women had chronic HCV before ART initiation.
- The proportion of visits with detectable HIV RNA was similar among women with and without chronic HCV (risk ratio, 1.19).
- 6 months after ART initiation, the proportion of visits with detectable HIV RNA among women with chronic HCV was 1.88 times that among women without HCV.
- At 2 years the ratio was 1.60, and by 6 years there was no difference.
Willis SJ, Cole SR, Westreich D, et al. Chronic hepatitis C virus infection and subsequent HIV viral load among women with HIV initiating antiretroviral therapy. [Published online ahead of print January 13, 2018]. AIDS. doi:10.1097/QAD.0000000000001745.
This Week's Must Reads
Must Reads in Hepatitis
Glecaprevir/Pibrentasvir Efficacy & Safety Assessed, J Hepatol; ePub 2018 Nov 23; D’Ambrosio, et al
HCV Infection Among Children & Young Persons, J Hepatol; ePub 2018 Nov 26; Modin, et al
HCV Patients with Limited Access to Antiviral Therapy, Dig Liver Dis; ePub 2018 Nov 29; Lens, et al
Progression in the Elimination of HCV Infection, PLoS One; ePub 2018 Dec 4; Juanbeltz, et al
Increased HCV Screening in Veteran Populations, Jt Comm J Qual Patient Saf; ePub 2018 Sep 25; Wray, et al